We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+21.74%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.87B
AUM Growth
+$435M
Cap. Flow
+$144M
Cap. Flow %
3.71%
Top 10 Hldgs %
35.18%
Holding
133
New
4
Increased
60
Reduced
11
Closed
5

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$39.2M
2
BPMC
Blueprint Medicines
BPMC
+$35.9M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$21.8M
4
WST icon
West Pharmaceutical
WST
+$21.2M
5
GOSS icon
Gossamer Bio
GOSS
+$19.7M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$64.6M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$20.5M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$15.4M
4
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$14.2M
5
EPZM
Epizyme, Inc
EPZM
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 96.71%
2 Consumer Staples 0.91%
3 Industrials 0.67%
4 Financials 0.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GH icon
76
Guardant Health
GH
$22.3B
$10.8M 0.28%
200,000
– –
FOLD
77
DELISTED
Amicus Therapeutics
FOLD
$10.6M 0.27%
1,012,506
– –
KDNY
78
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$9.98M 0.26%
507,512
– –
LUNG icon
79
Pulmonx
LUNG
$100M
$9.95M 0.26%
597,400
-105,000
-15% -$1.93M
OHPAU
80
DELISTED
Orion Acquisition Corp. Unit
OHPAU
$9.87M 0.25%
1,000,000
– –
AMYT
81
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$9.17M 0.24%
1,325,625
+13,000
+1% +$97K
KNTE
82
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$8.93M 0.23%
746,973
+128,589
+21% +$1.68M
HCAT icon
83
Health Catalyst
HCAT
$129M
$8.54M 0.22%
880,000
-65,400
-7% -$866K
NVTA
84
DELISTED
Invitae Corporation
NVTA
$8.33M 0.22%
3,386,855
-107,866
-3% -$327K
NKTX icon
85
Nkarta
NKTX
$165M
$8.11M 0.21%
616,277
– –
AUPH icon
86
Aurinia Pharmaceuticals
AUPH
$2.04B
$8.02M 0.21%
1,066,408
+251,282
+31% +$2.18M
DSGN icon
87
Design Therapeutics
DSGN
$894M
$7.7M 0.2%
460,391
– –
INZY
88
DELISTED
Inozyme Pharma
INZY
$7.52M 0.19%
2,807,618
+167,562
+6% +$606K
FOCL
89
EDAP TMS S.A.
FOCL
$231M
$7.51M 0.19%
910,000
– –
BMEA icon
90
Biomea Fusion
BMEA
$95M
$7.15M 0.18%
730,846
-354,894
-33% -$4.08M
GMDA
91
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$6.55M 0.17%
4,119,883
+1,944,883
+89% +$4.43M
MREO
92
Mereo BioPharma
MREO
$51.1M
$5.38M 0.14%
6,244,897
+14,622
+0.2% +$17.9K
BEAM icon
93
Beam Therapeutics
BEAM
$2.76B
$5.31M 0.14%
111,430
– –
EQRX
94
DELISTED
EQRx, Inc. Common Stock
EQRX
$4.95M 0.13%
1,000,000
– –
PRTK
95
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$4.46M 0.12%
1,734,037
– –
VIGL
96
DELISTED
Vigil Neuroscience
VIGL
$4.29M 0.11%
471,958
– –
MGNX icon
97
MacroGenics
MGNX
$258M
$4.17M 0.11%
1,206,642
+251,914
+26% +$964K
XLO icon
98
Xilio Therapeutics
XLO
$60.4M
$3.97M 0.1%
97,348
– –
FSTX
99
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$3.85M 0.1%
751,889
– –
OKUR
100
OnKure Therapeutics
OKUR
$165M
$3.83M 0.1%
114,319
– –
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Rock Springs Capital Management held 133 positions worth $3.87B, up 13% from $3.44B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rock Springs Capital Management deployed $144M of net new capital in Q3 2022, opening 4 new positions and adding to 60 existing holdings. Its largest new stake was Gossamer Bio: 1,586,962 shares worth $19M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Industrials.

On the sell side, the largest reduction was Shockwave Medical, Inc. Common Stock, an estimated $15.4M trimmed.

  • Rock Springs Capital Management's largest Q3 2022 buy was Gossamer Bio: 1,586,962 shares worth $19M.
  • Rock Springs Capital Management added most to Immunocore in Q3 2022, an estimated $39.2M increase.
  • Rock Springs Capital Management's biggest Q3 2022 reduction was Shockwave Medical, Inc. Common Stock, cutting an estimated $15.4M.
  • Rock Springs Capital Management fully exited Sierra Oncology, Inc. Common Stock in Q3 2022, selling an estimated $64.6M.
  • Rock Springs Capital Management's ten largest holdings make up 35% of its $3.87B portfolio in Q3 2022.
  • Rock Springs Capital Management opened 4 new positions and closed 5 in Q3 2022.
  • Rock Springs Capital Management's portfolio value rose 13% quarter-over-quarter to $3.87B.

Based on Rock Springs Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.